206 related articles for article (PubMed ID: 17031402)
21. Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei.
Nummela P; Leinonen H; Järvinen P; Thiel A; Järvinen H; Lepistö A; Ristimäki A
Hum Pathol; 2016 Aug; 54():47-54. PubMed ID: 27038681
[TBL] [Abstract][Full Text] [Related]
22. Synchronous Ovarian and Appendiceal Mucinous Neoplasms in the Absence of Pseudomyxoma Peritonei.
Gui X; Escobar J; Lee CH; Duggan MA; Köbel M
Int J Gynecol Cancer; 2017 Feb; 27(2):214-222. PubMed ID: 27870702
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women.
Ronnett BM; Shmookler BM; Diener-West M; Sugarbaker PH; Kurman RJ
Int J Gynecol Pathol; 1997 Jan; 16(1):1-9. PubMed ID: 8986525
[TBL] [Abstract][Full Text] [Related]
24. Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process.
Mohamed F; Gething S; Haiba M; Brun EA; Sugarbaker PH
J Surg Oncol; 2004 Apr; 86(1):10-5. PubMed ID: 15048674
[TBL] [Abstract][Full Text] [Related]
25. [Clinicopathologic characteristics of pseudomyxoma peritonei].
Zhou Q; Shi F; Zhao HY; Li Y; Song QK
Zhonghua Bing Li Xue Za Zhi; 2018 Mar; 47(3):192-195. PubMed ID: 29534359
[No Abstract] [Full Text] [Related]
26. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study.
Smeenk RM; van Velthuysen ML; Verwaal VJ; Zoetmulder FA
Eur J Surg Oncol; 2008 Feb; 34(2):196-201. PubMed ID: 17524597
[TBL] [Abstract][Full Text] [Related]
27. Pathological prognostic factors of pseudomyxoma peritonei: comprehensive clinicopathological analysis of 155 cases.
Yan F; Lin Y; Zhou Q; Chang H; Li Y
Hum Pathol; 2020 Mar; 97():9-18. PubMed ID: 31926211
[TBL] [Abstract][Full Text] [Related]
28. Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP).
Pillai K; Akhter J; Mekkawy A; Chua TC; Morris DL
Int J Med Sci; 2017; 14(1):18-28. PubMed ID: 28138305
[No Abstract] [Full Text] [Related]
29. Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment.
Kuracha MR; Thomas P; Loggie BW; Govindarajan V
Cancer Med; 2016 Apr; 5(4):711-9. PubMed ID: 26833741
[TBL] [Abstract][Full Text] [Related]
30. MUC2, MUC5AC and MUC5B in the mucus of a patient with pseudomyxoma peritonei: biochemical and immunohistochemical study.
Mall AS; Chirwa N; Govender D; Lotz Z; Tyler M; Rodrigues J; Kahn D; Goldberg P
Pathol Int; 2007 Aug; 57(8):537-47. PubMed ID: 17610480
[TBL] [Abstract][Full Text] [Related]
31. Mucin as a therapeutic target in pseudomyxoma peritonei.
Choudry HA; O'Malley ME; Guo ZS; Zeh HJ; Bartlett DL
J Surg Oncol; 2012 Dec; 106(7):911-7. PubMed ID: 22585683
[TBL] [Abstract][Full Text] [Related]
32. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.
Semino-Mora C; Liu H; McAvoy T; Nieroda C; Studeman K; Sardi A; Dubois A
Ann Surg Oncol; 2008 May; 15(5):1414-23. PubMed ID: 18299935
[TBL] [Abstract][Full Text] [Related]
33. Mucinous epithelial cysts of the spleen associated with pseudomyxoma peritonei.
Du Plessis DG; Louw JA; Wranz PA
Histopathology; 1999 Dec; 35(6):551-7. PubMed ID: 10583579
[TBL] [Abstract][Full Text] [Related]
34. Molecular profiles of high-grade and low-grade pseudomyxoma peritonei.
Noguchi R; Yano H; Gohda Y; Suda R; Igari T; Ohta Y; Yamashita N; Yamaguchi K; Terakado Y; Ikenoue T; Furukawa Y
Cancer Med; 2015 Dec; 4(12):1809-16. PubMed ID: 26475379
[TBL] [Abstract][Full Text] [Related]
35. Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases.
Carr NJ; Finch J; Ilesley IC; Chandrakumaran K; Mohamed F; Mirnezami A; Cecil T; Moran B
J Clin Pathol; 2012 Oct; 65(10):919-23. PubMed ID: 22718846
[TBL] [Abstract][Full Text] [Related]
36. In vivo model of pseudomyxoma peritonei for novel candidate drug discovery.
Chua TC; Akther J; Yao P; Morris DL
Anticancer Res; 2009 Oct; 29(10):4051-5. PubMed ID: 19846950
[TBL] [Abstract][Full Text] [Related]
37. Pseudomyxoma Peritonei as a First Manifestation of KRAS-Mutated Urachal Mucinous Cystadenocarcinoma of the Bladder: A Case Report.
Shelekhova KV; Zhuravlev AS; Krylova DD; Konstantinov AS; Shtan LV; Kheinshtein VA
Int J Surg Pathol; 2017 Sep; 25(6):563-566. PubMed ID: 28449606
[TBL] [Abstract][Full Text] [Related]
38. Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines.
Roberts DL; O'Dwyer ST; Stern PL; Renehan AG
Oncotarget; 2015 May; 6(13):10786-800. PubMed ID: 25929336
[TBL] [Abstract][Full Text] [Related]
39. Pseudomyxoma cutis; a new entity.
Terada T
Int J Clin Exp Pathol; 2013; 6(6):1169-76. PubMed ID: 23696938
[TBL] [Abstract][Full Text] [Related]
40. Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.
Amini A; Masoumi-Moghaddam S; Ehteda A; Morris DL
Orphanet J Rare Dis; 2014 May; 9():71. PubMed ID: 24886459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
